
|Articles|August 28, 2008
Medco and FDA to collaborate on pharmacogenomics
The groups have signed a two-year agreement.
Advertisement
Pharmacy benefit manager Medco and the Food and Drug Administration have signed a two-year agreement to develop pharmacogenomics research projects to study genetic testing and the effect of genetics on prescription drugs.
The research will initially focus on the blood-thinner warfarin but may later include oncology and virology. Medco and the FDA hope the research will help health professionals better select medications and dosages for individual patients.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
How Pharmacists Take Control of Medical Billing
2
Pharmacists Essential for Managing Patient Safety in Self-Medication
3
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
4
COVID-19 Booster Comparison Shows Higher Antibody Levels With mRNA Vaccine
5






























